Mario Balsa

913 posts

Mario Balsa banner
Mario Balsa

Mario Balsa

@MarioBalsaMD

Galleguiño 🌊 | Med Onc resident @ICO_oncologia | Skin cancer, IO & cell therapy 🎯 | 2025 Rotation Research @UTMDAnderson 🇺🇸 | @OncoAlert team💥 | Pianist 🎹

Barcelona, España Katılım Mart 2023
676 Takip Edilen1.5K Takipçiler
Sabitlenmiş Tweet
Mario Balsa
Mario Balsa@MarioBalsaMD·
✨ Our new review is OUT! Targeting claudins in gastric cancer sciencedirect.com/science/articl… From tight junction biology to real clinical impact 💥 ▪️ CLDN18.2: from “hidden” protein to actionable target ▪️ Beyond mAbs → ADCs, bsAbs & CAR-T incoming ▪️ CLDN6 & CLDN1 emerging as the next frontiers ▪️ Expression ≠ accessibility → biology matters Time to CLAUD-in on the opportunity and let gastric cancer finally GLOW in the SPOTLIGHT 💡 Thank you @DrMirallas @EduardoTB94 @CalvoMariona @tfleitask @BugesCris @RobertMontal for your great work! And special thanks to Dr. @chierrocarbo for her invaluable teaching and inspiration! 🧡 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @ICO_oncologia
Mario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet media
English
4
27
69
8.2K
Mario Balsa
Mario Balsa@MarioBalsaMD·
🫁 Lung cancer is no longer just about treating disease, it’s about intercepting its evolution! aacrjournals.org/cancerdiscover… This AACR roadmap lays out the shift: ▪️ From late-stage care → early detection & prevention ▪️ From static biology → dynamic tumor evolution ▪️ From single targets → multi-omic integration ▪️ From relapse treatment → MRD-driven intervention The future? Anticipate. Intercept. Adapt. @OncoAlert @OncoReporte @myESMO @_SEOM @LungCancerRx @Lung_Cancers
English
0
2
6
341
Mario Balsa
Mario Balsa@MarioBalsaMD·
🔎 Skin cancer screening in biologics-treated patients: 11-year real-world data in CIRD! sciencedirect.com/science/articl… 👥 636 screened at biologic start → only 1 cancer detected ▪️ Follow-up (~5 yrs): NMSC 10.1/1000 PY, melanoma 3.7/1000 PY 🎯 No significant link between biologics and melanoma risk 💥 Age, immunosuppression & steroids → NMSC signals Not all “biologics” behave biologically risky…sometimes the risk is just skin-deep🧴 @OncoAlert @OncoReporte @myESMO @_SEOM
Mario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet media
English
0
3
4
236
Mario Balsa retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
⚠️ Important to remember: 10% of patients on vepdegestrant are expected to develop QT prolongation (1.6% G3) — warranting caution in the coadministration of other QT-prolonging drugs
Oncology Brothers@OncBrothers

Vepdegestrant (PROTAC ER degrader) @US_FDA ✅ for HR+ metastatic breast based off #Veritac2 Ph III vs. (Fulvestrant) after CDK4/6i + AI: - mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57) - OS is immature - Well-tolerated, low discontinuation #bcsm @OncUpdates @OncoAlert

English
2
19
51
6.3K
Mario Balsa
Mario Balsa@MarioBalsaMD·
🚨 Important step forward in #PancreaticCancer 💥 FDA “safe to proceed” → EAP for daraxonrasib (RAS(ON) multi-selective inhibitor) ⚖️ Science meets urgency: access matters as much as efficacy Time to turn RAS(ON) into real-world ON for our patients🔥@OncoAlert @OncoReporte @_SEOM
Teresa Macarulla@MacarullaTeresa

@US_FDA allowed @RevMedicines to initiate an EAP for daraxonrasib. Let’s fight to ensure that PDAC patients around the world also have acces to it ASAP. @ACanPan @P_C_E_ #PancreaticCancer

English
0
5
9
884
Mario Balsa
Mario Balsa@MarioBalsaMD·
🚨 FDA approval in #BreastCancer VERITAC-2 delivers: vepdegestrant (protein degrader) in ER+/HER2− ESR1-mut 📉 PFS: 5.0 vs 2.1 mo (HR 0.57) 🎯 ORR: 19% vs 4% 🔍 Guardant360 CDx approved for ESR1 detection VERITAC-ly changing how we degrade resistance 🧬 @OncoAlert
OncoAlert@OncoAlert

FDA Approval in #BreastCancer based on VERITAC-2 buff.ly/u6s8WYi On May 1, 2026, the FDA approved vepdegestrant, a heterobifunctional protein degrader, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy. Approval was supported by the VERITAC-2 trial, where vepdegestrant improved progression-free survival versus fulvestrant (5.0 vs 2.1 months; HR 0.57) and increased response rates (19% vs 4%). Guardant360 CDx was simultaneously approved as a companion diagnostic to detect ESR1 mutations. Survival data remain immature at analysis. @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

English
0
2
4
365
Mario Balsa retweetledi
OncoAlert
OncoAlert@OncoAlert·
Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day Two Considerations for selection of ARPIs in older patients with mHSPC Presenter Dr. Dana Rathkopf 🇺🇸 Real-world veteran data suggest ADT plus ARPI benefits even older or frail men, though meta-analyses show reduced relative benefit in older versus younger patients, particularly in low-volume disease or with prostate radiotherapy. STOPCAP indicates abiraterone improves prostate cancer–specific survival but not overall survival, likely due to competing mortality. Treatment should be individualized: intensify therapy in fit patients, optimize reversible risks in vulnerable patients, and carefully weigh limited benefit versus toxicity in frail individuals. #ProstateCancer #ProstateCancerWeek @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @dmukherji @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
1
16
22
717
Mario Balsa retweetledi
OncoAlert
OncoAlert@OncoAlert·
GREAT JOB #APCCC26 WE Have not even started Day 2 and already 1️⃣ 1️⃣ .3️⃣ MILLION Impressions Worldwide #ProstateCancer #ProstateCancerWeek LUGANO🇨🇭 Thank you APCCC Faculty & Staff for an Amazing Meeting!! @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @dmukherji @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
OncoAlert tweet media
English
1
10
26
1.1K
Mario Balsa
Mario Balsa@MarioBalsaMD·
@AidaPiedraMD Mil mil gracias Aida! Qué bonito haber coincidido al final de mi etapa! Tienes un futuro brillante por delante ✨
Español
0
0
1
43
Aida Piedra, MD
Aida Piedra, MD@AidaPiedraMD·
Congratulations! @MarioBalsaMD great review! Tu período formativo no puede acabar mejor! Mucha suerte para lo que viene 👀
Mario Balsa@MarioBalsaMD

✨ Our new review is OUT! Targeting claudins in gastric cancer sciencedirect.com/science/articl… From tight junction biology to real clinical impact 💥 ▪️ CLDN18.2: from “hidden” protein to actionable target ▪️ Beyond mAbs → ADCs, bsAbs & CAR-T incoming ▪️ CLDN6 & CLDN1 emerging as the next frontiers ▪️ Expression ≠ accessibility → biology matters Time to CLAUD-in on the opportunity and let gastric cancer finally GLOW in the SPOTLIGHT 💡 Thank you @DrMirallas @EduardoTB94 @CalvoMariona @tfleitask @BugesCris @RobertMontal for your great work! And special thanks to Dr. @chierrocarbo for her invaluable teaching and inspiration! 🧡 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @ICO_oncologia

Español
1
0
2
175
Mario Balsa retweetledi
OncoAlert
OncoAlert@OncoAlert·
TOMORROW🇨🇭 LAKE LUGANO THE FIRST ANNUAL #APCCC5k 2026 🏃 A warm welcome , a great way to start the day with a fun Run/Walk around Lake Lugano Switzerland. See you There!! @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @dmukherji @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
English
0
4
10
644
Mario Balsa
Mario Balsa@MarioBalsaMD·
🧬 SEL1L: a new player in melanoma biology! From ER stress to tumor growth, this pathway matters! pubmed.ncbi.nlm.nih.gov/42031219/ 💡 SEL1L (ERAD/UPR component) upregulated in melanoma 💥 Higher expression → worse survival & more advanced disease ▪️ Correlates with tumor thickness, ulceration & microvessel density 🎯 Silencing SEL1L ↓ proliferation, ↑ apoptosis & necrosis || Anti-angiogenic shift (↑ THSP1/2) + ↓ vascularization From ER stress…to tumor stress; SEL1L might be the real “cell-1 villain” 🦠 @OncoAlert @OncoReporte @myESMO @_SEOM
English
1
3
4
343
Mario Balsa retweetledi
cinta hierro carbo
cinta hierro carbo@chierrocarbo·
📣First Gastric Cancer Preceptorship ICO-Badalona/B-ARGO/IGTP/CARE @ICO_oncologia @GTRecerca We shared how our Multidisciplinary Esophago-Gastric Functional Unit (UFEG) is organised 🩺🩻🏥while our Gastric Cancer Task Force fosters translational research🧫🧬 @AstraZeneca
cinta hierro carbo tweet media
English
0
3
12
342
Mario Balsa
Mario Balsa@MarioBalsaMD·
✨ Our new review is OUT! Targeting claudins in gastric cancer sciencedirect.com/science/articl… From tight junction biology to real clinical impact 💥 ▪️ CLDN18.2: from “hidden” protein to actionable target ▪️ Beyond mAbs → ADCs, bsAbs & CAR-T incoming ▪️ CLDN6 & CLDN1 emerging as the next frontiers ▪️ Expression ≠ accessibility → biology matters Time to CLAUD-in on the opportunity and let gastric cancer finally GLOW in the SPOTLIGHT 💡 Thank you @DrMirallas @EduardoTB94 @CalvoMariona @tfleitask @BugesCris @RobertMontal for your great work! And special thanks to Dr. @chierrocarbo for her invaluable teaching and inspiration! 🧡 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @ICO_oncologia
Mario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet media
English
4
27
69
8.2K
Mario Balsa retweetledi
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
⭐ #IPCS26 Day 2 Preview What to watch today 🔬 @OncoAlert @APCCC_Lugano #IPCS26 #APCCC26 @Silke_Gillessen @AOmlin After an outstanding Day 1, today we move deeper into precision oncology and emerging strategies in advanced prostate cancer. 🔹 Key sessions to follow: 🔹 Biomarkers & liquid biopsies → can we truly guide treatment decisions? 🔹 Molecular subtyping of mHSPC → towards better patient stratification 🔹 ctDNA & proteomics → dynamic disease monitoring 🔹 Immunotherapy & T-cell engagers → are we finally moving forward? 🔹 Tumor evolution & resistance → integrating biology into clinical trials 🔹 Don’t miss: 🔹 Novel immunotherapy approaches 🔹 Translational insights shaping next-generation trials 🔹 Cutting-edge data from selected abstracts 🔹 Expect: A strong focus on precision medicine, real-time monitoring and smarter trial design. @Silke_Gillessen @JTheurillat @mishabeltran @bjartell @ChrisSweens1 @DrMHofman @ProfKHerrmann @tompowles1 @EAntonarakis @declangmurphy @VedangMurthy @KOSJ12 @LoebStacy @DrYukselUrun @UrsulaVogl @fabioturco92 @nataliagandur @weoncologists @IPCSymposium @RenuEapen @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @DrRanaMcKay @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @EUplatinum @Uromigos #ProstateCancer #UroOncology #Oncology
Dra. María Natalia Gandur Quiroga tweet media
English
0
10
14
629
Mario Balsa
Mario Balsa@MarioBalsaMD·
@EduardoTB94 Thanks Edu!! Working with you on this has been a real pleasure. Your passion for the field really shows! ✨
English
0
0
0
48
Eduardo Terán
Eduardo Terán@EduardoTB94·
Congratulations on this outstanding deep review of the CLDN landscape in gastroesophageal tumors 🧬 🤩Delighted and grateful to be part of this work⁉️ Exciting novel targets on the horizon for more personalized treatments 💫#Oncology #PrecisionMedicine
Mario Balsa@MarioBalsaMD

✨ Our new review is OUT! Targeting claudins in gastric cancer sciencedirect.com/science/articl… From tight junction biology to real clinical impact 💥 ▪️ CLDN18.2: from “hidden” protein to actionable target ▪️ Beyond mAbs → ADCs, bsAbs & CAR-T incoming ▪️ CLDN6 & CLDN1 emerging as the next frontiers ▪️ Expression ≠ accessibility → biology matters Time to CLAUD-in on the opportunity and let gastric cancer finally GLOW in the SPOTLIGHT 💡 Thank you @DrMirallas @EduardoTB94 @CalvoMariona @tfleitask @BugesCris @RobertMontal for your great work! And special thanks to Dr. @chierrocarbo for her invaluable teaching and inspiration! 🧡 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @ICO_oncologia

English
2
3
13
1.9K
Mario Balsa
Mario Balsa@MarioBalsaMD·
@chierrocarbo Thank you so much Cinta!! Truly grateful for your leadership, mentorship, and constant inspiration! Excited for what’s coming next together! 🔝
English
0
0
1
73
cinta hierro carbo
cinta hierro carbo@chierrocarbo·
Great review by @MarioBalsaMD et al on how claudins are arrived to stay in the gastric cancer field!
Mario Balsa@MarioBalsaMD

✨ Our new review is OUT! Targeting claudins in gastric cancer sciencedirect.com/science/articl… From tight junction biology to real clinical impact 💥 ▪️ CLDN18.2: from “hidden” protein to actionable target ▪️ Beyond mAbs → ADCs, bsAbs & CAR-T incoming ▪️ CLDN6 & CLDN1 emerging as the next frontiers ▪️ Expression ≠ accessibility → biology matters Time to CLAUD-in on the opportunity and let gastric cancer finally GLOW in the SPOTLIGHT 💡 Thank you @DrMirallas @EduardoTB94 @CalvoMariona @tfleitask @BugesCris @RobertMontal for your great work! And special thanks to Dr. @chierrocarbo for her invaluable teaching and inspiration! 🧡 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @ICO_oncologia

English
2
1
7
428
Mario Balsa
Mario Balsa@MarioBalsaMD·
🚨 #APCCC26 is just around the corner! 🌍 High-level prostate cancer discussions + global experts + practice-changing insights incoming And yes, FREE for LMICs!! Don’t just watch the field evolve…be part of the consensus that shapes it 🎯 @OncoAlert
OncoAlert@OncoAlert

Dear Colleagues in Just a Few Days #APCCC26 Still Time for Online Registrations, FREE FOR LMICs ‼️ REGISTER HERE 👉 buff.ly/qYCDm7I @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum

English
0
3
5
1.2K
Mario Balsa
Mario Balsa@MarioBalsaMD·
🚨 MONETTE trial in PD-(L)1–resistant melanoma: ceralasertib ± durvalumab in a tough setting @CCR_AACR aacrjournals.org/clincancerres/… ▪️ ORR: 9.3% (combo) vs 5.8% (mono) ▪️ mPFS 2 months in both arms ▪️ mOS: 16.0 vs 12.3 months (trend, not definitive) ▪️ Manageable safety; biomarker hints (CD8+ T cells?) ATR-ing to break resistance! But this story is no Monet masterpiece…more like an impression still in progress 😌 @OncoAlert @OncoReporte @myESMO @_SEOM @MelanomaReAlli
English
0
4
10
986

Keşfet

@OncoAlert @OncoReporte @myESMO @_SEOM @LungCancerRx @Lung_Cancers @APCCC_Lugano @Silke_Gillessen